Home > Oncology > SABCS 2019 > Phase 3 Trial Update > S-1 shows promising results in combination with endocrine therapy

S-1 shows promising results in combination with endocrine therapy

Conference
SABCS 2019

The postoperative adjuvant use of the oral fluoropyrimidine S-1 significantly reduced invasive disease-free survival (iDFS) events and improved 5-year iDFS estimates in primary breast cancer patients having hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative disease in combination with standard endocrine therapy, with a feasible safety profile.

Although long-term prognostic outcomes of primary breast cancer patients have been improved remarkably in recent years, recurrence of the disease remains a serious problem. In a Japanese study, the usefulness of S-1 in combination with adjuvant endocrine therapy for primary breast cancer patients with luminal disease was assessed [1]. S-1 is a combination drug based on a biochemical modification of fluorouracil, containing tegafur, gimeracil, and oteracil in a molar ratio of 1:0.4:1. The study was designed as an open-label, randomised, phase 3 trial, and carried out in 139 centre...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on